drugset / Trial / NCT00962845
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
Phase 0
Completed
20 enrolled
Rutgers, The State University of New Jersey
National Cancer Institute (NCI) · collabRutgers Cancer Institute of New Jersey · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Studying samples of blood, tumor tissue, and skin in the laboratory from patients with melanoma receiving hydroxychloroquine may help doctors understand the effect of hydroxychloroquine on biomarkers. PURPOSE: This early phase I trial is studying hydroxychloroquine in patients with stage III or stage IV melanoma that can be removed by surgery.
Timeline
- Start
- 2010-09
- Primary completion
- 2013-05-30
- Completion
- 2013-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | 200 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 400 mg | Oral |